Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism.
Estramustine phosphate (Estracyt), a combination of estradiol and nitrogen mustard given to males with prostatic carcinoma, had the same effect on serum lipids, lipoproteins, and serum phosphoglyceride fatty acid composition as ethynyl estradiol (Etivex). The characteristic effects on serum lipids caused by both drugs, i.e., a reduction in serum cholesterol and an increase in serum phospholipids, were apparently expressions for reduced low density lipoproteins and increased alpha-lipoproteins. Serum lecithin fatty acid composition revealed during the administration of both drugs a characteristic increase in palmitic acid (16:0) and a decrease in stearic acid (18:0), interpreted as evidence for a cholestatic, although subclinical, liver involvement. Similar changes have earlier been revealed in women given ethynyl estradiol; however, the increase in serum triglycerides and very low density lipoprotein cholesterol in young women was not duplicated in aged males with prostatic carcinoma. Furthermore, in aged males, the administration of these estrogens did not change carbohydrate metabolism but did produce an increase in adipose tissue lipoprotein lipase.
D000273:Adipose Tissue / Q000378:metabolism; D000368:Aged; D050260:Carbohydrate Metabolism; D004961:Estramustine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005994:Glycerophosphates / Q000097:blood; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008071:Lipoprotein Lipase / Q000378:metabolism; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism
D005994:Glycerophosphates; D008055:Lipids; D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D008071:Lipoprotein Lipase